http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 허진득(Jin Duk Huh) (검색결과 6 건)
- 무료
- 기관 내 무료
- 유료
-
-
-
그레이브스병에 있어서 항갑상선제와 티록신 병합요법의 효과
조장현(Jang Hyun Cho),오기창(Ki Chang Oh),김명원(Myung Won Kim),김원석(Won Seok Kim),추진호(Jin Ho Choo),조형철(Hyung Cheol Cho),김순호(Soon Ho Kim),임중규(Joong Kyu Lim),허진득(Jin Duk Huh) 대한내과학회 1998 대한내과학회지 Vol.54 No.2
N/A Objectives: It was recently reported that the administration of T during antithyroid drug(ATD) therapy resulted in a significant decrease of antibodies to TSH receptors as well as the rate of recurrence of active Graves' disease following discontinuance of ATD treatment. But, there is still controversy whether combination therapy is efficient. Therefore, the present study was undertaken to evaluate the effect of T4 administration of patient with Graves' disease who were being treated with ATD. Methods: We studied 56 patients received methimazole(MMI) alone(Group 1) and 48 patients received methimazole plus T4(Group 2). They are diagnosed active Graves' disease at department of internal medicine, Kwang ju Christian Hospital from January, 1994 to December, 1995. AU the patients were treated initially with 30mg of methimazole daily for one month after then, in the Group 1(methimazole alone), the dose of methimazole was adjusted as necessary to achieve normal serum concentrations of T3, T4, and TSH. The patients of Group 2(methimazole plus T4) continue to receive the combination of T4 at a dose of 100 μg daily. Simultaneously, we estimated the serum concentratio n of T3, T4, TSH and Thyroid-stimulating immunoglob ulin(TSI) antibody at every three months. Results : We obtained the following result. In the group 1, mean TSI values were 50.1%(first visit), 30.6%(6months), and 24.7%(1year). And, in the group 2 mean TSI values were 51.8%(first visit), 33.6%(6months), and 22.7% (1year). After 6 months of discontinuing of therapy, the recurrence rate was no significant difference in the two groups (the recurrence rate were 55.4%, 50.0%, respectively P>0.05). Conclusion : These results suggest that T4 administration in combination with MMI therapy have no significant effect in a decrease in levels of TSH receptors antibodies and recurrence rate within 6 months discontinuing MMI therapy as compared with MMI treatment alone.
-
김호동,김연종,임중규,허진득,윤형신,장진형,김훤,손장신 대한내분비학회 1992 Endocrinology and metabolism Vol.7 No.2
Adrenal cortical carcinoma is a rare tumor that affects all ages and sexes and has a dismal prognosis. Half are functioning and half are not. Functioning neoplasma of the adrenal cortex are clinically manifested by virilization, Cushing's syndrome, feminization, or hyperaldosteronism. A 22-year-old female was admitted to our hospital in April 1990, because of amenorrhea for 6 months, hirsuitism, acne and palpable mass in left upper abdomen for 3 months. Routine laboratory examination including blood chemistry gave no abnormalities. Abdoiminal CT scan demonstrated a large mass with central necrosis and calcification, about 10×15 cm size in left upper abdomen. Endocrine tests revealed; serum testosterone 7.5ng/dl, DHEA-sulfate above 1,000ng/dl, 24-hour urine free cortisol 152 ng/day, 17-KS 50.8 ng/day, 17-OHCS 9.9mg/day. Plasma aldosterone and plasma renin activity were elevated. We report a case of adrenocortical carcinoma with hypersecretion of glucocorticoid and androgen.She also had a secondary aldosteronsm and lung metastasis. She underwent surgical resection of the tumor and treated with mitotan (O.P'-DDD) postoperatively (J Kor Soc Endocrinol 7:160~164, 1992).
-
임동명,김순호,임중규,허진득,장진형,김훤,위대철,윤철승 대한내분비학회 1992 Endocrinology and metabolism Vol.7 No.4
The syndrome of polyostotic fibrous dysplasia (PFD), cutaneous pigmentation and endocrinopathy (Albright's syndrome) continuous today to remain enigmatic. Not all patient with PFD have complete syndrome. In addition to the described in Albright's original patients, other endocrinopathies have been reported, including hyperthyroidism, acromegaly, hyperparathyroidism, Cushing's syndrome, adenoma of pituitary, thyroid, parathyroid and adrenal gland, vitamine Dresistant rickets and hypothalamic hypogonadotrophic hypogonadism. A 27-year-old man was found to have polyostotic fibrous dysplasia of bone, cutaneous pigmentation and acromegaly with diabetes mellitus. He started to have pain in left hip joint and it caused an alternation on his gait in 1983. X-ray study revealed that he had fibrous dysplasia. He gradually developed clinical feature of acromegaly. Subsequent biochemical study of growth hormone and radiologic study of the sellar confirmed the diagnosis of acromegaly. Bone biopsy and microscopic examination of the pituitary tumor tissue obtained through transsphenoidal procedure were reported to be fibrous dysplasia and acidophilic adenoma, respectively. The purpose of this report is to describe a patient with incomplete Albright's syndrome with acromegaly, which is very rare and we believe this is the first case to be reported in Korean literature.(J Kor Soc Endocrinol 7:402~408, 1992)
-
김순호,오기창,추진호,임중규,조형철,조장현,허진득 대한내분비학회 1997 Endocrinology and metabolism Vol.12 No.1
Background: Clinically apparent thyroid nodule is a very common disease in adults. Patients are often treated with thyroxine in order to reduce the size of the nodule, but the efficacy of thyroxine-suppressive therapy with thyroxine remains uncertain. We investigated the efficacy of thyroxine-suppressive therapy and the hormonal characteristics during thyroxine therapy to find out whether such measurement could be used to determine the effectiveness of this therapy in patients with benign solitary thyroid nodule proved by aspiration biopsy. Methods: In this study, 54 patients were randomly assigned to receive L-thyroxine(Group I, n=24) or placebo(GroupII, n=30) for 1 year. High resolution ultrasonography(10MHz) was used to measure the size of the nodules at six month intervals. Thyroid hormones and thyroglobulin assay and FNA(fine needle aspiration) was done at the same time. The dose of thyroxine was 200ug/day. Patients were followed at 6 month intervals. Results: The results were as follows: 1) 13(54.1%) out of 24 Group I patients after adequate TSH suppression had a statistically significant reduction of nodule size and before-to-after nodule volume ratios were significantly different between the Group I and Group II patients. 2) In the responders among Group I patients, the before-to-after therapy ratio of the nodule volume was not related to the pretreatment nodule size, thyroid hormones and thyroglobulin levels. Conclusion: Thus we concluded that an adequate suppressive dose of L-thyroxine significantly altered the volume of the benign solitary thyroid nodules 12 months later. ( J Kor Soc Endocrinol 12:45-52, 1997)
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
